Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S. Tewari(University of California, Irvine Medical Center), Michael W. Sill(Roswell Park Comprehensive Cancer Center), Richard T. Penson(Massachusetts General Hospital), Helen Huang(University at Buffalo, State University of New York), Lois M. Ramondetta(The University of Texas MD Anderson Cancer Center), Lisa M. Landrum(University of Oklahoma), Ana Oaknin(Vall d'Hebron Hospital Universitari), Thomas Reid(University of Cincinnati Medical Center), Mario M. Leitão(Memorial Sloan Kettering Cancer Center), Helen E. Michael(Indiana University School of Medicine), Philip J. DiSaia(University of California, Irvine Medical Center), Larry J. Copeland(The Ohio State University), William T. Creasman(Medical University of South Carolina), Frederick B. Stehman(Indiana University School of Medicine), Mark F. Brady(Roswell Park Comprehensive Cancer Center), Robert A. Burger(University of Pennsylvania), J.T. Thigpen(University of Mississippi Medical Center), Michael J. Birrer(Massachusetts General Hospital), Steven Waggoner(Case Western Reserve University), David H. Moore(Franciscan Health Indianapolis), Katherine Y. Look, Wui-Jin Koh(University of Washington), Bradley J. Monk(The US Oncology Network)
Cited by 676Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis